Grants and Contributions:
Title:
Vertical Integration of Antibody Discovery for Next-Generation Biotherapeutics
Agreement Number:
921989
Agreement Value:
$2,617,300.00
Agreement Date:
Jan 1, 2019 - Mar 31, 2022
Description:
This project will develop, validate, and integrate new technologies to create a platform for the discovery of therapeutic antibodies against any target class, and with industry-leading speed, throughput, and efficiency.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Vancouver, British Columbia, CA V5Y 0A1
Reference Number:
172-2018-2019-Q4-921989
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
838509446
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 274 days.
Amendment Date
Oct 1, 2020
Recipient's Operating Name:
AbCellera
Recipient's Legal Name:
AbCellera Biologics Inc.
Federal Riding Name:
Vancouver Granville
Federal Riding Number:
59036
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710
Amendments: